MA17R: Disease-Free Survival with Extended Adjuvant Letrozole in Postmenopausal Women with Early-Stage Breast Cancer (BC) Letrozole (n = 959) Placebo (n. - ppt download
Frontiers | Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients | International Journal of Clinical Oncology
Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
Gaining Further Perspective into Treatment of Advanced Breast Cancer with CDK4/6 Inhibitors - The Medical Xchange
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up | Breast Cancer Research and Treatment
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 -
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates | Breast Cancer Research | Full Text
Cancers | Free Full-Text | Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Yara Abdou, MD on X: "PALOMA-2: OS update ❗️Palbo+ET did NOT significantly improve OS compared to PBO+ET ❓Is there a difference btw CDK4/6i ⚠️Interpret with caution given missing survival data and distinct
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib | npj Precision Oncology
![ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202206/13831_14395_1052.jpg "ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR")
ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 -
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
2021 Update on Systemic Therapy for Breast Cancer | Published in healthbook TIMES Oncology Hematology
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
